 |
|
|
Sudafed Blocked Nose Capsules (pack of 24) |
|
SUDAFED® Blocked Nose Capsules are used to help clear stuffy noses that normally occur with colds, hay fever and other allergies. The capsules contain phenylephrine hydrochloride, an effective decongestant that can help clear your nose, relieving that blocked up feeling and enabling you to get on with your day.
|
|
For the relief of nasal congestion associated with colds and hay fever.
Active ingredient
mg/cap
Phenylephrine hydrochloride
12.00
|
|
Adults and children over 12 years: One capsule if necessary, up to four times daily.
Children under 12 years: Not recommended.
Elderly: There is no need for dosage reduction in the elderly.
|
|
Hypersensitivity to any of the ingredients. Avoid in patients with cardiovascular disease, diabetes mellitus, closed angle glaucoma, hyperthyroidism, prostatic enlargement and phaeochromocytoma.
This medicine should be used with caution in patients with occlusive vascular disease including Raynaud's Phenomenon.
Do not take for longer than 7 days, unless your doctor agrees.
If symptoms do not go away talk to your doctor.
Keep all medicines out of the reach of children.
Warning: Do not exceed the stated dose.
Should not be given to patients being treated with monoamine oxidase inhibitors or within 14 days of stopping such treatment. May enhance the effects of anticholinergic drugs such as tricyclic antidepressants. May increase the possibility of arrhythmias in digitalised patients. May enhance the cardiovascular effects of other sympathomimetic amines (e.g. decongestants).
This medicine should not be taken together with vasodilators, beta-blockers or enzyme inducers such as alcohol.
The safety of this medicine during pregnancy and lactation has not been established but in view of a possible association of foetal abnormalities with first trimester exposure to phenylephrine, the use of the product during pregnancy should be avoided. In addition, because phenylephrine may educe placental perfusion, the product should not be used in patients with a history of pre-eclampsia. In view of the lack of data on the use of phenylephrine during lactation, this medicine should not be used during breast-feeding.
|
|
Phenylephrine is a sympathomimetic agent with mainly direct effects on adrenergic receptors. It has predominantly alpha adrenergic activity and is without stimulating effects on the central nervous system. The sympathomimetic effect of phenylephrine produces vasoconstriction which in turn relieves nasal congestion.
Phenylephrine is readily absorbed after oral administration but is subject to extensive presystemic metabolism, much of which occurs in the enterocytes. As a consequence, systemic bioavailability is only about 40%. Following oral administration, peak plasma concentrations are achieved in 1-2 hours. The mean plasma half life is in the range 2-3 hours. Penetration into the brain appears to be minimal.
Following absorption, the drug is extensively metabolised in the liver. Both phenylephrine and its metabolites are excreted in the urine.
The volume of distribution is between 200 and 500 litres, but there are no data on the extent of plasma protein binding.
List of excipients
Pregelatinised maize starch
Dried maize starch
Lactose monohydrate
Magnesium stearate
Hard Gelatin Capsule (Gelatin, Quinoline yellow E104, Titanium dioxide E171)
Ink (Black iron oxide E172, Shellac, propylene glycol)
|
|
|
